First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

Neuropharmacology

Volumn 89, Issue , 2015, Pages 193-203

  Kelly, Julie A ^a   Boyle, Noreen T ^a   Cole, Natalie ^b   Slator, Gillian R ^a   Colivicchi, M Alessandra ^c   Stefanini, Chiara ^c   Gobbo, Oliviero L ^d   Scalabrino, Gaia A ^d   Ryan, Sinead M ^e   Elamin, Marwa ^a   Walsh, Cathal ^d   Vajda, Alice ^a   Goggin, Margaret M ^a   Campbell, Matthew ^d   Mash, Deborah C ^f   O'Mara, Shane M ^d   Brayden, David J ^e   Callanan, John J ^e,g   Tipton, Keith F ^d   Della Corte, Laura ^c   Hunter, Jackie ^h   O'Boyle, Kathy M ^e   Williams, Carvell H ⁱ   Hardiman, Orla ^a   more..

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF FLORENCE   (Italy)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g ROSS UNIVERSITY SCHOOL OF VETERINARY MEDICINE   (Saint Kitts and Nevis)

^h OI Pharma Partners Ltd   (United Kingdom)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

JAK4D; Neurodegeneration; Neuroprotection; Novel central TRH receptor subtype; Thyrotropin releasing hormone; TRH receptors

Indexed keywords

JAK4D; NEUROPROTECTIVE AGENT; PROTIRELIN; UNCLASSIFIED DRUG; PROTEIN BINDING; PROTIRELIN RECEPTOR;

ADVERSE OUTCOME; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; NERVE CELL LESION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; C57BL MOUSE; CACO 2 CELL LINE; DISEASE MODEL; DOSE RESPONSE; HUMAN; METABOLISM; MIDDLE AGED; MOUSE; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; RANDOMIZATION; TRANSGENIC MOUSE; WISTAR RAT;

ANIMALS; BRAIN; CACO-2 CELLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, THYROTROPIN-RELEASING HORMONE; THYROTROPIN-RELEASING HORMONE;

EID: 84922276023     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.09.024     Document Type: Article

References (71)

1. S. Al-Sarraj, A. King, C. Troakes, B. Smith, S. Maekawa, I. Bodi, B. Rogelj, A. Al-Chalabi, T. Hortobágyi, and C.E. Shaw p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS Acta Neuropathol. 122 2011 691 702 10.1007/s00401-011-0911-2
2. I. Bidaud, L. Galas, M. Bulant, B.G. Jenks, D.T.W.M. Ouwens, S. Jégou, A. Ladram, E.W. Roubos, M.-C. Tonon, P. Nicolas, and H. Vaudry Distribution of the mRNAs encoding the thyrotropin-releasing hormone (TRH) precursor and three TRH receptors in the brain and pituitary of Xenopus laevis: effect of background color adaptation on TRH and TRH receptor gene expression J. Comp. Neurol. 477 2004 11 28 10.1002/cne.20235
3. I. Bidaud, P. Lory, P. Nicolas, M. Bulant, and A. Ladram Characterization and functional expression of cDNAs encoding thyrotropin-releasing hormone receptor from Xenopus laevis Eur. J. Biochem. 269 2002 4566 4576
4. G. Boschi, M. Desiles, V. Reny, R. Rips, and S. Wrigglesworth Antinociceptive properties of thyrotropin releasing hormone in mice: comparison with morphine Br. J. Pharmacol. 79 1983 85 92
5. J. Cao, D. O'Donnell, H. Vu, K. Payza, C. Pou, C. Godbout, A. Jakob, M. Pelletier, P. Lembo, S. Ahmad, and P. Walker Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor J Biol Chem. 273 1988 32281 32287
6. A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini, and C. Melchiorre Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 51 2008 347 372 10.1021/jm7009364
7. A. Chronopoulos, C. Stafstrom, S. Thurber, P. Hyde, M. Mikati, and G.L. Holmes Neuroprotective effect of felbamate after kainic acid-induced status epilepticus Epilepsia 34 1993 359 366
8. J. Cooper-Knock, C. Hewitt, J.R. Highley, A. Brockington, A. Milano, S. Man, J. Martindale, J. Hartley, T. Walsh, C. Gelsthorpe, L. Baxter, G. Forster, M. Fox, J. Bury, K. Mok, C.J. McDermott, B.J. Traynor, J. Kirby, S.B. Wharton, P.G. Ince, J. Hardy, and P.J. Shaw Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72 Brain 135 2012 751 764 10.1093/brain/awr365
9. R. D'Hooge, and P.P. De Deyn Applications of the Morris water maze in the study of learning and memory Brain Res. Rev. 36 2001 60 90 10.1016/S0165-0173(01)00067-4
10. C.M. Daimon, P. Chirdon, S. Maudsley, and B. Martin The role of thyrotropin releasing hormone in aging and neurodegenerative diseases Am. J. Alzheimers. Dis. (Columbia, Mo.) 1 2013 10.7726/ajad.2013.1003
11. S.J. Enna, and M. Williams Challenges in the search for drugs to treat central nervous system disorders J. Pharmacol. Exp. Ther. 329 2009 404 411 10.1124/jpet.108.143420
12. A.I. Faden, V.A. Movsesyan, S.M. Knoblach, F. Ahmed, and I. Cernak Neuroprotective effects of novel small peptides in vitro and after brain injury Neuropharmacology 49 2005 410 424 10.1016/j.neuropharm.2005.04.001
13. W. Freinbichler, M.A. Colivicchi, M. Fattori, C. Ballini, K.F. Tipton, W. Linert, and L. Della Corte Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis J. Neurochem. 105 2008 738 749 10.1111/j.1471-4159.2007.05168.x
14. W. Freinbichler, M.A. Colivicchi, C. Stefanini, L. Bianchi, C. Ballini, B. Misini, P. Weinberger, W. Linert, D. Varešlija, K.F. Tipton, and L. Della Corte Highly reactive oxygen species: detection, formation, and possible functions Cell. Mol. Life Sci. 68 2011 2067 2079 10.1007/s00018-011-0682-x
15. K.A. Gary, K.A. Sevarino, G.G. Yarbrough, A.J. Prange, and A. Winokur The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics J. Pharmacol. Exp. Ther. 305 2003 410 416 10.1124/jpet.102.044040
16. H. Geerts Of mice and men: bridging the translational disconnect in CNS drug discovery CNS Drugs 23 2009 915 926 10.2165/11310890-000000000-00000
17. W.J. Geldenhuys, M.B.H. Youdim, R.T. Carroll, and C.J. Van der Schyf The emergence of designed multiple ligands for neurodegenerative disorders Prog. Neurobiol. 94 2011 347 359 10.1016/j.pneurobio.2011.04.010
18. S.R. George, B.F. O'Dowd, and S.P. Lee G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug Discov. 1 2002 808 820 10.1038/nrd913
19. A. Gill, J. Kidd, F. Vieira, K. Thompson, and S. Perrin No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS PLoS One 4 2009 10.1371/journal.pone.0006489
20. D.E. Gloriam, R. Fredriksson, and H.B. Schiöth The G protein-coupled receptor subset of the rat genome BMC Genomics 8 2007 338 10.1186/1471-2164-8-338
21. O.L. Gobbo, and S.M. O'Mara Combining exercise and cyclooxygenase-2 inhibition does not ameliorate learning deficits after brain insult, despite an increase in BDNF levels Brain Res. 1046 2005 224 229
22. E. Gonzalez-Rey, A. Chorny, and M. Delgado Regulation of immune tolerance by anti-inflammatory neuropeptides Nat. Rev. Immunol. 7 2007 52 63 10.1038/nri1984
23. E.C. Griffiths Clinical applications of thyrotropin-releasing hormone Clin. Sci. (Lond) 73 1987 449 457
24. M.E. Gurney, H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D. Alexander, J. Caliendo, A. Hentati, Y.W. Kwon, and H.X. Deng Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation Science 264 1994 1772 1775
25. W.D. Hirst, J.A. Minton, S.M. Bromidge, S.F. Moss, A.J. Latter, G. Riley, C. Routledge, D.N. Middlemiss, and G.W. Price Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue Br. J. Pharmacol. 130 2000 1597 1605 10.1038/sj.bjp.0703458
26. 2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2 Neurosci. Lett. 431 2008 26 30 10.1016/j.neulet.2007.11.013
27. Y. Huang, and L. Mucke Alzheimer mechanisms and therapeutic strategies Cell 148 2012 1204 1222 10.1016/j.cell.2012.02.040
28. H. Itadani, T. Nakamura, J. Itoh, H. Iwaasa, A. Kanatani, J. Borkowski, M. Ihara, and M. Ohta Cloning and characterization of a new subtype of thyrotropin-releasing hormone receptors Biochem. Biophys. Res. Commun. 250 1998 68 71 10.1006/bbrc.1998.9268
29. D. Jantas, L. Jaworska-Feil, A.W. Lipkowski, and W. Lason Effects of TRH and its analogues on primary cortical neuronal cell damage induced by various excitotoxic, necrotic and apoptotic agents Neuropeptides 43 2009 371 385 10.1016/j.npep.2009.07.002
30. B. Kalmar, S. Novoselov, A. Gray, M.E. Cheetham, B. Margulis, and L. Greensmith Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS J. Neurochem. 107 2008 339 350 10.1111/j.1471-4159.2008.05595.x
31. J. Kamath, G.G. Yarbrough, A.J. Prange, and a Winokur The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis Pharmacol. Ther. 121 2009 20 28 10.1016/j.pharmthera.2008.09.004
32. J.A. Kelly, G.R. Slator, K.F. Tipton, C.H. Williams, and K. Bauer Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides J. Biol. Chem. 275 2000 16746 16751 10.1074/jbc.M910386199
33. J.A. Kelly Thyrotropin-releasing hormone: basis and potential for its therapeutic use Essays Biochem. 30 1995 133 149
34. J.A. Kelly, G.A. Scalabrino, G.R. Slator, A.A. Cullen, J.F. Gilmer, D.G. Lloyd, G.W. Bennett, K. Bauer, K.F. Tipton, and C.H. Williams Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II Biochem. J. 389 2005 569 576 10.1042/BJ20041722
35. 3H][3-methyl-histidine(2)]TRH Biochem. Pharmacol. 63 2002 2197 2206
36. K.P. Kenna, R.L. McLaughlin, S. Byrne, M. Elamin, M. Heverin, E.M. Kenny, P. Cormican, D.W. Morris, C.G. Donaghy, D.G. Bradley, and O. Hardiman Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing J. Med. Genet. 50 2013 776 783 10.1136/jmedgenet-2013-101795
37. P. Klivenyi, R.J. Ferrante, R.T. Matthews, M.B. Bogdanov, A.M. Klein, O.A. Andreassen, G. Mueller, M. Wermer, R. Kaddurah-Daouk, and M.F. Beal Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis Nat. Med. 5 1999 347 350 10.1038/6568
38. S. Knippenberg, N. Thau, R. Dengler, and S. Petri Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS) Behav. Brain Res. 213 2010 82 87 10.1016/j.bbr.2010.04.042
39. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 10.1038/nrd1470
40. M.J. Kubek, and B.P. Garg Thyrotropin-releasing hormone in the treatment of intractable epilepsy Pediatr. Neurol. 26 2002 9 17 10.1016/S0887-8994(01)00321-6
41. X. Lu, I. Bidaud, A. Ladram, and M.C. Gershengorn Pharmacological studies of thyrotropin-releasing hormone (TRH) receptors from Xenopus laevis: is xTRHR3 a TRH receptor? Endocrinology 144 2003 1842 1846 10.1210/en.2002-221074
42. A.C. Ludolph, C. Bendotti, E. Blaugrund, A. Chio, L. Greensmith, J.-P. Loeffler, R. Mead, H.G. Niessen, S. Petri, P.-F. Pradat, W. Robberecht, M. Ruegg, B. Schwalenstöcker, D. Stiller, L. van den Berg, F. Vieira, and S. von Horsten Guidelines for preclinical animal research in ALS/MND: a consensus meeting Amyotroph. Lateral Scler. 11 2010 38 45 10.3109/17482960903545334
43. A.C. Ludolph, C. Bendotti, E. Blaugrund, B. Hengerer, J.-P. Löffler, J. Martin, V. Meininger, T. Meyer, S. Moussaoui, W. Robberecht, S. Scott, V. Silani, and L.H. Van Den Berg Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop Amyotroph. Lateral Scler. 8 2007 217 223 10.1080/17482960701292837
44. S. Manaker, A. Eichen, A. Winokur, C.H. Rhodes, and T.C. Rainbow Autoradiographic localization of thyrotropin releasing hormone receptors in human brain Neurology 36 1986 641 646
45. A. Markou, C. Chiamulera, M.A. Geyer, M. Tricklebank, and T. Steckler Removing obstacles in neuroscience drug discovery: the future path for animal models Neuropsychopharmacology 34 2009 74 89 10.1038/npp.2008.173
46. A.C. McKee, R.A. Stern, C.J. Nowinski, T.D. Stein, V.E. Alvarez, D.H. Daneshvar, H.-S. Lee, S.M. Wojtowicz, G. Hall, C.M. Baugh, D.O. Riley, C.A. Kubilus, K.A. Cormier, M.A. Jacobs, B.R. Martin, C.R. Abraham, T. Ikezu, R.R. Reichard, B.L. Wolozin, A.E. Budson, L.E. Goldstein, N.W. Kowall, and R.C. Cantu The spectrum of disease in chronic traumatic encephalopathy Brain 136 2013 43 64 10.1093/brain/aws307
47. G. Miller Is pharma running out of brainy ideas? Science 329 2012 502 504 Online
48. L. Mucke, and D.J. Selkoe Neurotoxicity of amyloid β-protein: synaptic and network dysfunction Cold Spring Harb. Perspect. Med. 2 2012 a006338 10.1101/cshperspect.a006338
49. B.F. O'Dowd, D.K. Lee, W. Huang, T. Nguyen, R. Cheng, Y. Liu, B. Wang, M.C. Gershengorn, and S.R. George TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared with TRH-R1 Mol. Endocrinol. 14 2000 183 193 10.1210/mend.14.1.0407
50. J.J. Palop, J. Chin, and L. Mucke A network dysfunction perspective on neurodegenerative diseases Nature 443 2006 768 773 10.1038/nature05289
51. J.J. Palop, and L. Mucke Epilepsy and cognitive impairments in Alzheimer disease Arch. Neurol. 66 2009 435 440 10.1001/archneurol.2009.15
52. M.N. Pangalos, L.E. Schechter, and O. Hurko Drug development for CNS disorders: strategies for balancing risk and reducing attrition Nat. Rev. Drug Discov. 6 2007 521 532 10.1038/nrd2094
53. W.M. Pardridge Molecular biology of the blood-brain barrier Mol. Biotechnol. 30 2005 57 70 10.1385/MB:30:1:057
54. W.M. Pardridge Alzheimer's disease drug development and the problem of the blood-brain barrier Alzheimers. Dement. 5 2009 427 432 10.1016/j.jalz.2009.06.003
55. C.R. Parker, and A. Capdevila Thyrotropin releasing hormone (TRH) binding sites in the adult human brain: localization and characterization Peptides 5 1984 701 706 10.1016/0196-9781(84)90010-X
56. J. Portelli, Y. Michotte, and I. Smolders Ghrelin: an emerging new anticonvulsant neuropeptide Epilepsia 53 2012 585 595 10.1111/j.1528-1167.2012.03423.x
57. S.M. Ryan, X. Wang, G. Mantovani, C.T. Sayers, D.M. Haddleton, and D.J. Brayden Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate J. Control. Release 135 2009 51 59 10.1016/j.jconrel.2008.12.014
58. Y. Saito, M. Mekuchi, N. Kobayashi, M. Kimura, Y. Aoki, T. Masuda, T. Azuma, M. Fukami, M. Iigo, and T. Yanagisawa Molecular cloning, molecular evolution and gene expression of cDNAs encoding thyrotropin-releasing hormone receptor subtypes in a teleost, the sockeye salmon (Oncorhynchus nerka) Gen. Comp. Endocrinol. 174 2011 80 88 10.1016/j.ygcen.2011.07.011
59. G.A. Scalabrino, N. Hogan, K.M. O'Boyle, G.R. Slator, D.J. Gregg, C.M. Fitchett, S.M. Draper, G.W. Bennett, P.M. Hinkle, K. Bauer, C.H. Williams, K.F. Tipton, and J.A. Kelly Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone Neuropharmacology 52 2007 1472 1481 10.1016/j.neuropharm.2007.02.003
60. S. Scott, J.E. Kranz, J. Cole, J.M. Lincecum, K. Thompson, N. Kelly, A. Bostrom, J. Theodoss, B.M. Al-Nakhala, F.G. Vieira, J. Ramasubbu, and J.A. Heywood Design, power, and interpretation of studies in the standard murine model of ALS Amyotroph. Lateral Scler. 9 2008 4 15 10.1080/17482960701856300
61. S.Y. Shin, S.H. Lee, S.T. Yang, E.J. Park, D.G. Lee, M.K. Lee, S.H. Eom, W.K. Song, Y. Kim, K.S. Hahm, and J.I. Kim Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs J. Pept. Res. 58 2001 504 514
62. B. Stoica, K. Byrnes, and A.I. Faden Multifunctional drug treatment in neurotrauma Neurotherapeutics 6 2009 14 27 10.1016/j.nurt.2008.10.029
63. Q.-J. Sun, R.-S. Duan, A.-H. Wang, W. Shang, T. Zhang, X.-Q. Zhang, and Z.-F. Chi Alterations of NR2B and PSD-95 expression in hippocampus of kainic acid-exposed rats with behavioural deficits Behav. Brain Res. 201 2009 292 299 10.1016/j.bbr.2009.02.027
64. Y. Sun, X. Lu, and M.C. Gershengorn Thyrotropin-releasing hormone receptors - similarities and differences J. Mol. Endocrinol. 30 2003 87 97
65. N. Thirunarayanan, E.A. Nir, B.M. Raaka, and M.C. Gershengorn Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice Neuropsychopharmacology 38 2013 950 956 10.1038/npp.2012.256
66. D. Triguero, J. Buciak, and W.M. Pardridge Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins J. Neurochem. 54 1990 1882 1888
67. P. Vlieghe, V. Lisowski, J. Martinez, and M. Khrestchatisky Synthetic therapeutic peptides: science and market Drug Discov. Today 15 2010 40 56 10.1016/j.drudis.2009.10.009
68. C.V. Vorhees, and M.T. Williams Morris water maze: procedures for assessing spatial and related forms of learning and memory Nat. Protoc. 1 2006 848 858 10.1038/nprot.2006.116
69. M. Yamada, K. Hashimoto, T. Satoh, N. Shibusawa, H. Kohga, Y. Ozawa, S. Yamada, and M. Mori A novel transcript for the thyrotropin-releasing hormone receptor in human pituitary and pituitary tumors J. Clin. Endocrinol. Metab. 82 1997 4224 4228 10.1210/jcem.82.12.4438
70. C. Zhou, Y. Huang, and S. Przedborski Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance Ann. N. Y. Acad. Sci. 1147 2008 93 104 10.1196/annals.1427.023
71. J.-L. Zhou, T.N. Shatskikh, X. Liu, and G.L. Holmes Impaired single cell firing and long-term potentiation parallels memory impairment following recurrent seizures Eur. J. Neurosci. 25 2007 3667 3677 10.1111/j.1460-9568.2007.05598.x